KORU Medical Systems, Inc. (NASDAQ: KRMD) – Q4 2025 Earnings
KORU Medical Systems, Inc. (NASDAQ: KRMD) – Q4 2025 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
KORU Medical Systems sells subcutaneous infusion systems, mainly pumps and consumables used to deliver drugs under the skin, with its core business still driven by SCIg (subcutaneous immunoglobulin) therapy, a recurring home-infusion market. The customer base is primarily specialty pharmacies, home-infusion providers, and increasingly pharma partners using KORU’s system in clinical and commercial settings. KORU appears to occupy a niche leadership position in large-volume subcutaneous infusion, especially in home use, but it is now trying to expand beyond its legacy Ig market into broader drug categories and new care settings such as infusion clinics. Financially, 2025 looks like a real improvement year: revenue grew 22%, adjusted EBITDA turned positive, cash burn narrowed sharply, and international growth accelerated, although GAAP profitability has not yet been reached and gross margin softened. Near-term themes are clear: international prefilled syringe expansion, new on-label drug approvals, diversification beyond SCIg, and a CEO transition that seems strategically steady rather than disruptive.
Quarterly Results
Earnings Release Date: Mar. 12, 2026
Stock Price: $4.51
Market Cap: $208.3 million
Q4 2025 sales of $10.9 million vs $8.8 million in the prior year
Q4 2025 Non-GAAP Adjusted EPS of $0.01 vs ($0.02) in the prior year
Q4 2025 GAAP Diluted EPS of ($0.01) vs ($0.03) in the prior year
Quick Takeaway
KORU Medical Systems is in a growth-to-scaled-profitability phase, focusing on protecting its SCIg base, expanding internationally, and broadening its platform into additional drugs and care settings. The call’s strongest positives were international pre-fill momentum, infusion-clinic entry, pharma pipeline additions, and the expectation of repeat positive EBITDA and cash flow, while the biggest concerns are timing risk on approvals/conversions and the fact that several newer growth vectors are still early. Execution on 2026 cadence, especially international rollout and new-drug traction, will be critical.
Press Release vs Call Transcript Comparison
The biggest investing takeaway is that the press release reads like a good quarter from a small medtech company, while the call makes it sound more like a platform story nearing a commercial broadening phase. The release is numbers-first: 22% full-year growth, positive adjusted EBITDA, improved cash usage, and a handful of regulatory and pipeline wins. The call is more revealing because it shows how management thinks those pieces connect: international prefilled syringe adoption feeds volume growth, RYSTIGGO opens infusion clinics, infusion clinics create a path toward oncology and other non-SCIg therapies, and the existing SG&A base may allow incremental revenue to carry attractive leverage.
That said, the call also quietly lowers the risk of over-excitement. Management is not saying oncology or the newer pharma opportunities are major 2026 revenue contributors today. They are saying the company has planted commercial and regulatory seeds that could matter more over the next several quarters and years. That distinction is important. For an investor, the story is not “hidden blockbuster now”; it is “the company may be transitioning from a single-therapy niche player into a broader subcutaneous delivery platform, but the monetization curve will likely be staged.”
Investor Underappreciation Signals
✅International Prefill Ramp — The press release tells you Europe certification happened, but the call reveals a rolling country launch cadence with one to two new markets potentially coming online each quarter, which means investors may be modeling certification as a static event instead of a multi-quarter revenue engine.
✅Infusion-Clinic Beachhead — RYSTIGGO looks like a single drug approval in the press release, but the call shows it may be the company’s first real commercial entry into infusion clinics, a channel that could support more therapies and faster oncology penetration later.
✅Operating Leverage Story — Revenue growth of 22.2% with only 2.9% operating expense growth already shows leverage, and the call suggests that leverage should continue because SG&A is not scaling one-for-one with revenue, which the market may not fully credit until EBITDA expands further.
✅Pipeline Volume Embedded in Small Revenue Line — Pharma Services looks small and slightly down in the press release, but the call ties two new deals to roughly 3 million annual infusions, so investors focused only on current milestone revenue may be missing the future commercial value of those programs.
✅Domestic Share Gain vs. Market Growth — The release mentions market growth and account gains, but the call makes clear Q4 domestic growth was above market and helped by account wins, which means KORU may be competitively stronger than a simple SCIg market-growth beneficiary.
✅Japan Re-emergence — Japan is absent from the release, yet the call frames it as a $0.5 million to $1.0 million opportunity with approvals already in place and prefilled syringes as the unlock, making it an easy-to-miss source of upside if execution improves.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
The transcript itself does not contain a meaningful discussion of U.S. tariffs or trade policy. There were no comments in the Q&A about tariff effects on revenue, supply chain, profitability, market share, or innovation. There were also no mitigation actions described in the call, such as shifting sourcing, changing production footprint, repricing, or renegotiating contracts.
So the clean conclusion from the transcript is: no actionable tariff read-through was provided on this call. Investors should not assume tariffs are irrelevant, only that management did not address them here.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
Q3 2025: KORU’s narrative centered on execution and validation, highlighting strong SCIg growth, accelerating international traction, and clear progress toward profitability. Management emphasized consistent revenue growth, share gains, and improving financial discipline, positioning the business as a high-quality operator within a growing niche. The story was straightforward: the model is working and scaling.Q4 2025: The narrative shifted toward platform expansion and future optionality, with greater emphasis on infusion clinics, oncology entry, and a broader drug-delivery ecosystem. Management framed KORU as evolving beyond SCIg into a multi-channel, multi-therapy platform, while reinforcing sustained profitability and operating leverage. The story moved from proving the business to expanding its long-term opportunity set, albeit with more reliance on execution timing.
Year-over-year comparison
Q4 2024: KORU’s narrative was centered on disciplined execution, highlighting consistent double-digit growth, margin expansion, and improving cash efficiency. Management focused on validating the strength of its core SCIg business, early international expansion, and building a pipeline that could support future growth. The story was about proving the model works and establishing a stable foundation.
Q4 2025: The narrative shifted toward platform expansion, with greater emphasis on international rollout cadence, infusion clinic entry, and broader drug-delivery opportunities beyond SCIg. Management positioned the company as evolving into a multi-channel, multi-therapy platform while reinforcing sustained profitability and operating leverage. The story moved from execution to scaling a larger, more complex growth opportunity that depends on timing and continued execution.